Gilead Cites 'More Sophisticated' Process As Pressure For A Major Deal Increases

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

CEO John Milligan offered few details about Gilead's deal strategy during an investor conference last week, but analysts think internal pressure for a major deal is beginning to equal the external sentiment, including an analyst who sees Incyte as a likely target, but not a quick fix for Gilead's declining HCV drug sales.

chess

The ongoing decline of its hepatitis C revenues has put additional pressure on Gilead Sciences Inc. to make a significant purchase that might boost its forward momentum – something that apparently is as clear inside the virology powerhouse as outside – but recent commentary by CEO John Milligan leaves doubt as to whether the firm is willing to greatly change the parameters of what it seeks in a transaction.

Milligan spoke on March 14 at the Barclay's Global Healthcare Conference, during which analyst Geoff Meacham tried to draw him...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip